Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Next-Generation Sequencing in Non- BCR-ABL Mechanisms Resistance in Patients with Chronic Myeloid Leukemia: Results of a Pilot Study

Ilya Buldakov, Sergey Voloshin, MD PhD, Mikhail Fominykh, MD, Vasily Shuvaev, MD, Sergey Petrov, Alexander Chechetkin, MD PhD, Irina Martynkevich, MD PhD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-142391

Published: 2020

Journal Articles

ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

Francois-Xavier Mahon, MD PhD, Nelma D Clementino, MD, Mikhail Fominykh, MD, Jeffrey H. Lipton, MD PhD, Anna G. Turkina, Prof., MD, Beatriz Moiraghi, MD, Franck E Nicolini, MDPhD, Naoto Takahashi, MD PhD, Tomasz Sacha, MDPhD, Dong-Wook Kim, MD, Rafik Fellague-Chebra, MD, Ranjan Tiwari, MSc, Catherine Bouard, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-136250

Published: 2020

Journal Articles

Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice

Vasily Shuvaev, MD, Olga Vinogradova, MD PhD, Irina Martynkevich, MD PhD, Novitskaya Natalya, MD, Mikhail Fominykh, MD, Svetlana Tsareva, Dzhariyat Shikhbabaeva, Maria Pankrashkina, Mikhail Chernikov, Nikolay Sharkunov, MD PhD, Irina Zotova, MD, Vera Udaleva, MD PhD, Ekaterina Motyko, MD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5446.

https://doi.org/10.1182/blood-2018-99-114164

Published: 2018

Journal Articles

Role of Molecular Drivers in Coagulation By Integral Assessment in Primary Myelofibrosis Patients

Elizaveta Efremova, MD, Olesya Matvienko, MD, Natalya Korsakova, Mikhail Fominykh, MD, Natalya Silina, Ludmila Papayan, Lyubov Polushkina, MD, Ekaterina Motyko, MD, Irina Martynkevich, MD PhD, Vasily Shuvaev, MD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2018-99-118801

Published: 2018

Journal Articles

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Natalia Lazorko, MD, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Irina Martynkevich, Mikhail Fominykh, MD, Anna Silyutina, MD, Katerina Ovsiannikova, Nadia Siordia, MD, Andrey Zaritskey, Elena Machulaytene, MD

Blood (2017) 130 (Supplement 1): 5255.

https://doi.org/10.1182/blood.V130.Suppl_1.5255.5255

Published: 2017

Journal Articles

Influence of JAK2V617F Allele Burden on Hematological Response in the Treatment of Polycythemia Vera

Dzhariyat Shikhbabaeva, MD, Vasily Shuvaev, MD, Regina Golovchenko, MD PhD, Vera Udaleva, MD, Mikhail Fominykh, MD, Irina I Zotova, MD, Lyubov Polushkina, MD, Irina Martynkevich, DSc, Kudrat Abdulkadyrov, MD PhD

Blood (2016) 128 (22): 5475.

https://doi.org/10.1182/blood.V128.22.5475.5475

Published: 2016

Journal Articles

Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Mikhail Fominykh, MD, Vasily Shuvaev, MD, Irina Martynkevich, DSc, Oleg Shukhov, MD, Ekaterina Chelysheva, MD, Anna G Turkina, Prof., MD, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5437.

https://doi.org/10.1182/blood.V128.22.5437.5437

Published: 2016

Journal Articles

Prognosis in Primary Myelofibrosis Patients According to Cytogenetic and Molecular Testing Results

Liubov Polushkina, Irina Martynkevich, DSc, Vasily Shuvaev, MD, Mikhail Fominykh, MD, Dzhariyat Shikhbabaeva, MD, Ekaterina Motyko, PhD, Lyudmila Martynenko, Natalya Cybakova, PhD, Marina Ivanova, MD PhD, Elena Shabanova, Anastasya Zhernyakova, Alsu Savrilova, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5467.

https://doi.org/10.1182/blood.V128.22.5467.5467

Published: 2016

Journal Articles

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

Vasily Shuvaev, MD, Mikhail Fominykh, MD, Vera Udaleva, MD, Irina I Zotova, MD, Regina Golovchenko, MD PhD, Dzhariyat Shikhbabaeva, MD, Irina Martynkevich, DSc, Lyudmila Martynenko, Marina Ivanova, MD PhD, Natalya Tsybakova, PhD, Ekaterina Motyko, PhD, Lyubov Polushkina, MD, Nadezhda Potikhonova, MD PhD, Sophya Tyranova, MD PhD, Marina Zenina, MD PhD, Kudrat Abdulkadyrov, MD PhD

Blood (2016) 128 (22): 5441.

https://doi.org/10.1182/blood.V128.22.5441.5441

Published: 2016

Journal Articles

It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics

Blood (2016) 128 (22): 5442.

https://doi.org/10.1182/blood.V128.22.5442.5442

Published: 2016

Journal Articles

Aplastic Anemia Associated with PNH-Clone - a Single Centre Experience

Elena Shilova, MD PhD, Tatiana Glazanova, MD Dr.Sci, Zhanna Chubukina, PhD, Lubov Stelmashenko, MD PhD, Sergey Gritsaev, MD Dr.Sci, Mikhail Fominykh, MD, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5080.

https://doi.org/10.1182/blood.V128.22.5080.5080

Published: 2016

Journal Articles

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

Blood (2015) 126 (23): 5150.

https://doi.org/10.1182/blood.V126.23.5150.5150

Published: 2015

Journal Articles

The Influence of Hemostasis Genetic Features on Thrombosis Rates in Patients with Polycythemia Vera

Dzhariyat Shikhbabaeva, Vasily Shuvaev, MD, Sergey Kapustin, PhD, Irina Martynkevich, MD PhD, Vera Udaleva, MD, Regina Golovchenko, MD, Tatyana Zamotina, Mikhail Fominykh, MD, Irina Zotova, Lyubov Polushkina, Kudrat Abdulkadyrov, MD PhD

Blood (2015) 126 (23): 5180.

https://doi.org/10.1182/blood.V126.23.5180.5180

Published: 2015

Journal Articles

Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

Vasily Shuvaev, MD, Kudrat Abdulkadyrov, MD PhD, Anna Turkina, Prof., MD, Irina Martynkevich, MD PhD, Ekaterina Chelysheva, MD PhD, Mikhail Fominykh, MD, Valentin Martchenko

Blood (2015) 126 (23): 3293.

https://doi.org/10.1182/blood.V126.23.3293.3293

Published: 2015

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Elza Lomaia, MD PhD, Andrey Zaritskey, MD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Mikhail Fominykh, MD, Ekaterina Ovsyannikova, MD, Natalia Lazorko, MD, Natalia Matyuhina, MS, Pavel Butylin, PhD, Elena Machyulaitene, MD, Evgenia Salamatova, MD, Kudrat Abdulkadyrov, MD PhD

Blood (2015) 126 (23): 4051.

https://doi.org/10.1182/blood.V126.23.4051.4051

Published: 2015

Journal Articles

Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment

Blood (2014) 124 (21): 3148.

https://doi.org/10.1182/blood.V124.21.3148.3148

Published: 2014

Journal Articles

Genetic and Epigenetic Alterations of Ph-Negative Myeloproliferative Neoplasms

Lyubov Polushkina, Irina Martynkevich, PhD, Vasily Shuvaev, MD, Ekaterina Petrova, Lyudmila Martynenko, Natalya Cybakova, MD, Marina Ivanova, MD, Elizaveta Kleina, Elena Shabanova, Dzhariyat Shikhbabaeva, Tatyana Zamotina, Mikhail Fominykh, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5549.

https://doi.org/10.1182/blood.V124.21.5549.5549

Published: 2014

Journal Articles

Ph-Negative Chronic Myeloproliferative Neoplasms – Population Analysis, a Single Center 10-years’ Experience

Vasily Shuvaev, MD, Irina Martynkevich, PhD, Alla Abdulkadyrova, Vera Udaleva, MD, Tatyana Zamotina, Mikhail Fominykh, Regina Golovchenko, Irina Zotova, Dzhariyat Shikhbabaeva, Lyubov Polushkina, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5556.

https://doi.org/10.1182/blood.V124.21.5556.5556

Published: 2014

Journal Articles

Early Molecular Response in Chronic Myeloid Leukemia Patients Predicts Future Response Status

Irina Martynkevich, PhD, Vasily Shuvaev, MD, Ekaterina Petrova, Lyubov Polushkina, Lyudmila Martynenko, Marina Ivanova, MD, Natalya Cybakova, MD, Elizaveta Kleina, Elena Shabanova, Mikhail Fominykh, Kudrat Abdulkadyrov, MD

Blood (2014) 124 (21): 5529.

https://doi.org/10.1182/blood.V124.21.5529.5529

Published: 2014

NARROW

Next-Generation Sequencing in Non- BCR-ABL Mechanisms Resistance in Patients with Chronic Myeloid Leukemia: Results of a Pilot Study

ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice

Role of Molecular Drivers in Coagulation By Integral Assessment in Primary Myelofibrosis Patients

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Influence of JAK2V617F Allele Burden on Hematological Response in the Treatment of Polycythemia Vera

Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Prognosis in Primary Myelofibrosis Patients According to Cytogenetic and Molecular Testing Results

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics

Aplastic Anemia Associated with PNH-Clone - a Single Centre Experience

The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

The Influence of Hemostasis Genetic Features on Thrombosis Rates in Patients with Polycythemia Vera

Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment

Genetic and Epigenetic Alterations of Ph-Negative Myeloproliferative Neoplasms

Ph-Negative Chronic Myeloproliferative Neoplasms – Population Analysis, a Single Center 10-years’ Experience

Early Molecular Response in Chronic Myeloid Leukemia Patients Predicts Future Response Status

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only